The Links Between Executive and Linguistic Processes and Their Lesional Determinants From a Verbal Fluency Task
NCT ID: NCT05875103
Last Updated: 2025-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
302 participants
INTERVENTIONAL
2023-05-16
2029-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Indeed, the lesion determinants of this task remain to be clarified despite remarkable advances due to the evolution of imaging techniques (voxel-based lesion-symptom mapping (VLSM); voxel-based morphometry (VBM)).
Furthermore, while the direct assessment of linguistic process, semantic memory, and processing speed is well defined, the examination of the executive component (i.e., strategic search process) remains unsettled and will be undertaken in this study.
This work will take advantage of data from previous multicenter work, validated methodologies for both analysis and interpretation of cognitive performance as well as anatomic-clinical correlations at the voxel level and will be performed in cognitive neurodegenerative and cerebrovascular disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cognitive Control of Language
NCT03124173
Establishing the Language Network With Independent Component Analysis of Resting State MRI
NCT02577757
Influence of Age on Hemispheric Lateralization of Language : a Longitudinal Study
NCT00241293
Neural Correlates of Intern Speech
NCT02830100
Investigation of Neurophysiological Functioning During Oral Comprehension Task
NCT06178276
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cognitive cortical neurodegenerative diseases and stroke PATIENTS
linguistic processes
Linguistic processes are assessed by performance score on the following tests:
* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)
* vocabulary test (Mill Hill - Deltour, 1993),
* repetition tests (Gremots - Bézy et al., 2016),
* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)
* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),
* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),
* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
linguistic processes
Linguistic processes are assessed by performance score on the following tests:
* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)
* vocabulary test (Mill Hill - Deltour, 1993),
* repetition tests (Gremots - Bézy et al., 2016),
* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)
* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),
* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),
* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* informed consentPatients between 40 and 85 years old,
* French native language,
* Social Security affiliation,
* Can read, write and count (up to 36) and knows the alphabet
* Assessed in Amiens University Memory Clinic for:
* Mild severity impairment (MMSE\> 19) or major severity impairment related to:
* AD according to Albert criteria and McKhann criteria
* DCL according to McKeith criteria
* FTLD according to Rascovsky criteria
* CBD according to Armstrong's criteria
* PSP according to Höglinger criteria
* For Stroke PATIENTS
* informed consent
* Patients between 40 and 85 years old,
* French native language,
* Social Security affiliation,
* Can read, write and count (up to 36) and knows the alphabet
* Having suffered a stroke, hospitalized in neurology, visualized by imaging
Exclusion Criteria
* Other current or past brain condition affecting cognition, including:
* Severe head trauma
* Epilepsy prior to stroke still requiring previous treatment
* Parkinson disease, multiple sclerosis
* Brain tumor or brain radiation therapy
* Current or past schizophrenia or psychosis
* Active or past psychiatric impairments requiring a stay\> 2 days in a specialized environment
* Contra indication to MRI
* Comorbidity with life expectancy \<1 year
* Comorbidity affecting cognition in particular:
* Alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome
* Opiate or cocaine addiction or opiate withdrawal syndrome
* Renal failure (dialysis or creatinine clearance \<30)
* Hepatic failure (spontaneous INR\> 1.5 or PT \<60%)
* Respiratory failure requiring oxygen therapy
* Heart failure (orthopnea\> 2 pillows)
* Persistent vigilance disorder (NIHSS1a score ≤1)
* Cancer with paraneoplastic syndrome
* Treatment with gold salts, D Penicillamine or other treatment with cognitive effect
* Patient under guardianship or curators or private under public law
* Pregnant and / or lactating woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire, Amiens
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens
Amiens, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PI2022_843_0150
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.